] i ) triggers insulin secretion. Thus, the K ATP channel links metabolic alterations to the electrical activity of the beta cells. Naively, reduced or absent K ATP channel activity is expected to result in constitutive membrane depolarisation, elevated [Ca 2+ ] i and hypersecretion of insulin. In humans, heterozygous loss-of-function mutations of beta cell K ATP subunits (SUR1, encoded by the gene ABCC8, and Kir6.2, encoded by the gene KCNJ11) underlie congenital hyperinsulinaemia (CHI) [1] [2] [3] [4] [5] [6] [7] , a rare genetic disease characterised by relative hyperinsulinaemia, which generally presents with high insulin levels in parallel with low blood glucose [8] .
K ATP channels are an obligate complex of Kir6.2 and SUR1 subunits [9] [10] [11] . Mice completely lacking Kir6.2 or SUR1 [12] [13] [14] , as well as mice expressing a dominantnegative Kir6.2 transgene in beta cells (Kir6. 2 [AAA] [15] or Kir6.2[G132S] [16] ) have been generated. Kir6.2 [AAA] mice (which exhibit complete loss of K ATP channels in ∼70% of beta cells, but normal channel density in the remainder) show hyperinsulinaemia, enhanced glucose tolerance and increased glucose-stimulated insulin secretion (GSIS) [15] . However, mice completely lacking K ATP activity (Kir6. show glucose intolerance and loss of insulin secretion as adults [12] [13] [14] 17] . Thus, genetic abolition of beta cell K ATP channels in mice fails to recapitulate some features of CHI, whereas a transgenic model of reduced K ATP does reiterate a hyperinsulinaemic phenotype throughout life. We have therefore proposed that, while complete absence may cause insulin secretory failure as in Kir6.2 and SUR1 knockout (KO) mice [12, 13, 17, 18] , partial loss of beta cell K ATP channel activity in vivo, as observed in dominant-negative Kir6. 2 [AAA] mice, causes insulin hypersecretion. Here we further test this hypothesis, and show that the reduced K ATP gene dosage in heterozygous Kir6.2 +/− and SUR1 +/− mice causes reduced K ATP and insulin hypersecretion without progression to secretory failure.
Materials and methods

Generation of transgenic mice Kir6.2
−/− mice were originally generated by targeted disruption of the gene encoding for Kir6.2 in an outbred genetic strain using E14 embryonic stem (ES) cells established from the 129Sv mouse strain (a gift from S. Seino and T. Miki, Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan) [14] . SUR1 −/− mice (a gift from [12, 14] . Kir6.2[AAA] were generated and maintained on the C57/Bl6 background [15] .
Isolation of pancreatic islets and beta cells All experiments were performed in compliance with the relevant laws and institutional guidelines, and were approved by the Washington University Animal Studies Committee. Mice were anaesthetised with 2-bromo-2-chloro-1,1,1-trifluoroethane in an anaesthetising chamber and killed by cervical dislocation. Pancreata were cannulated and injected with Hank's balanced salt solution (Sigma, St Louis, MO, USA) containing collagenase (Type XI [Sigma]) (0.3 mg/ml, pH 7.4) [18] . Briefly, pancreata were digested for 5 min at 37°C, hand shaken and washed three times in cold Hank's solution [18] . Islets were manually isolated under a dissecting microscope, and maintained overnight in CMRL medium (Gibco BRL) containing 5.6 mmol/l glucose in a humidified 37°C incubator. For electrophysiological measurements, islets were washed three times in Minimal Essential Medium (without L-glutamine), followed by one wash in DMEM supplemented with trypsin/EDTA (0.01/0.002%), and a final wash in DMEM [15] . Trypsin-treated islets were dispersed into isolated cells by resuspending gently in complete CMRL medium (supplemented with FCS, 10%), penicillin (100 U/ml) and streptomycin (100 μg/ml). Isolated cells were plated on glass coverslips.
Electrophysiological measurements Macroscopic currents from dispersed islet cells were recorded using a standard whole-cell voltage-clamp configuration [15] . Electrodes were filled with K-INT (140 mmol/l KCl, 10 mmol/l K-HEPES, 1 mmol/l K-EGTA, pH 7.4), plus 1 mmol/l MgCl 2 and 1 mmol/l ATP (potassium salt). Experiments were digitised into a microcomputer using Pclamp8.0 (Axon Instruments, La Jolla, CA, USA) software. Off-line analysis was performed using EXCEL (Microsoft).
Rb
+ efflux experiments Isolated islets were pre-incubated for 1 h with 86 Rb + (as rubidium chloride, 1.5 mCi/ml; Amersham Biosciences). Loaded islets were placed in microcentrifuge tubes (30 per group) and washed twice with RPMI-1640 medium (Sigma) at 37°C. 86 Rb + efflux was assayed by replacing the bathing solution with Ringer's solution with metabolic inhibitor (MI), with or without 1 μmol/l glibenclamide. MI solution contained 2.5 mg/ml oligomycin, 1 mmol/l 2-deoxyglucose, together with 10 mmol/l tetraethylammonium to block voltage-gated K + channels and 10 μmol/l nifedipine to block Ca 2+ entry. The bathing solution was replaced with fresh solution every 5 min over a 40-min period, and counted in a scintillation counter. 86 Rb + efflux in the presence or absence of glibenclamide was fitted by a single exponential (see Fig. 1a ). The reciprocal of the exponential time constant (rate constant) for each efflux experiment is then proportional to the K + (Rb + ) conductance in the islet membranes.
Blood glucose and insulin levels Whole blood was assayed for blood glucose using the glucose dehydrogenase-based enzymatic assay and quantified using a Glucometer Elite Xl meter (Bayer, Elkhart, IN, USA). Plasma insulin was measured using a rat insulin ELISA kit (Crystal Chem, Chicago, IL, USA). Intraperitoneal glucose tolerance tests (GTTs) were done on 12-week-old mice following a 16-h fast. Animals were injected i.p. with glucose (1.0 g/kg body weight).
Insulin-release experiments Following overnight incubation in CMRL (low glucose, 5.6 mmol/l) islets (ten per well in 12-well plates) were pre-incubated in DMEM plus 3 mmol/l glucose for 2 h. The islets were incubated in DMEM plus glucose as indicated for 60 min at 37°C and medium was removed and assayed for insulin content as described above. Experiments were repeated in triplicate. Isolated islets were sonicated on ice prior to estimation of insulin content per islet.
Confocal imaging of microfluidic-device-trapped islets Devices were fabricated using the elastomer polydimethylsiloxane as described [19] . Islets were labelled with 4 μmol/l Fluo-4 (Molecular Probes, Eugene, OR, USA) at room temperature for 2 h in imaging buffer (125 mmol/l NaCl, 5.7 mmol/l KCl, 2.5 mmol/l CaCl 2 , 1.2 mmol/l MgCl 2 , 10 mmol/l HEPES, 2 mmol/l glucose and 0.1% BSA, pH 7.4). Imaging was performed using an LSM 510 microscope with a 20×0.75 NA Fluar objective lens (Carl Zeiss, Thornwood, NY, USA). The device was held on the microscope in a humidified temperature-controlled stage (Carl Zeiss) for imaging at 37°C. Fluo-4 was imaged using the 488 nm laser line and the long-pass 505 nm emission filter. Images were collected at 2-s intervals for a period of 2 min after incubation for at least 10 min in 2, 4, 6, 8 or 10 mmol/ l glucose.
Image analysis Images were analysed with MetaMorph 5.0 (Universal Imaging Corp., Downington, PA, USA). In order to determine the glucose dependence of intracellular Ca 2+ oscillations, 'Ca 2+ -active' cells were identified and outlined while the islets were incubated in 8 mmol/l glucose. Ca 2+ -active cells (at 8 mmol/l glucose) were defined as cells that exhibited clear, synchronised increase of fluorescence (F/F 0 ) from baseline, as illustrated in Fig. 5 . Then, the same outlined cells (Ca 2+ -active cells at 8 mmol/l glucose) were analysed for Ca 2+ oscillations at lower and higher glucose concentrations. Glucose dependence of Ca 2+ from the whole islet was also measured. The fraction of cells showing synchronised oscillations was then estimated at each glucose concentration (Fig. 5c ).
Statistical analysis Data are presented as means±SEM. Differences between samples were compared using the Student's t-test or ANOVA and post hoc Duncan's test, as appropriate. A difference was defined as significant when p<0.05. Non-significant differences are not indicated in the figures. Figure 1a shows sample fluxes from each of the examined genotypes in the presence and absence of the channel blocker glibenclamide. Fluxes were fitted by single exponentials (time constants are indicated by arrowheads in Fig. 1a) , and reciprocal rate constant are plotted in Fig. 1b +/+ beta cells was also measured using a whole-cell membrane patch-clamp. Maximum resting membrane potential (in zero glucose) was similar (∼−75 mV) in both genotypes, but consistent with the 86 Rb + flux measurements from intact islets, whole-cell K + current peak during wholecell perfusion with zero ATP was greatly reduced (by ). Islet insulin content was determined in parallel with insulin secretion from non-glucose-challenged islets (50-100 islets in replicates of 10, from each animal). Total insulin content was not significantly different among the genotypes (Fig. 4b) [21] . Labelled islets were exposed to increasing concentrations of glucose (2-10 mmol/l), for at least 10 min in each concentration. Synchronised Ca 2+ activity from individual beta cells within the islet was observed in both Kir6.2 +/+ and Kir6.2 +/− islets at 8 mmol/l glucose (Fig. 5a) . We therefore tracked whole-islet Ca (Fig. 5a,b) . By contrast, most Kir6.2 +/− islets showed Ca 2+ oscillations at 6 mmol/l glucose (Fig. 5a,b) . The fraction of Ca 2+ -active cells is shown in Fig. 5c . At lower glucose concentrations (2 and 4 mmol/l) the fraction of Ca 2+ -active cells was negligible in both genotypes (Fig. 5c) +/− islet. b Relative fluorescence intensity (F/F 0 ) vs time taken from each outlined cell in a (black traces) and from the whole islets (red traces) in a are shown at 6 and 8 mmol/l glucose. The timing of the frames in a are indicated (i and ii). (Fig. 4) .
Results
Heterozygous
Heterozygous SUR1
+/− islets reiterate reduced K ATP channel density, insulin hypersecretion, and mildly enhanced glucose tolerance Given the strict stoichiometry between SUR1 and Kir6.2 in the generation of K ATP channels, it is expected that loss of either subunit should have similar effects on K ATP channel density. As shown in Fig. 6a,b , there is no glibenclamide-sensitive 86 
Rb
+ flux in SUR1 −/− islets.
Intermediate fluxes in SUR1 +/− islets represent ∼60% reduction in the glibenclamide-sensitive rate constants, again indicating a similar reduction in K ATP conductance to that seen in heterozygous Kir6.2 +/− islets (Fig. 1) . We examined the whole-animal consequences of this reduced beta cell K ATP conductance. Although fasted blood glucose was not different between wild-type and SUR1 +/− littermates ( Fig. 6e) , fed blood glucose was slightly lower (Fig. 6f) , as seen in Kir6.2 +/− mice. Similarly, SUR1
+/− mice showed slightly enhanced glucose tolerance compared with littermate controls, whereas SUR1 −/− mice were extremely glucose-intolerant (Fig. 6c) . Consistent with the differential whole-animal phenotypes, isolated SUR1 +/− islets also displayed increased GSIS (Fig. 6d) . Maximum insulin release (in 23 mmol/l glucose plus glibenclamide) was again similar in SUR1 +/+ and SUR1 +/− islets and much lower in SUR1 −/− islets (Fig. 6d) .
Discussion
Decreased K ATP channel activity and insulin secretion in vivo: predictions vs findings It is now clear that K ATP channels are a critical link between glucose metabolism and insulin secretion, underlined by the finding that gain of K ATP activity can cause permanent neonatal diabetes mellitus (PNDM) [22] [23] [24] [25] whereas CHI results from lossof-function K ATP mutations [5, [26] [27] [28] [29] [30] . We previously described a mouse model of beta cell K ATP gain-of-function that reiterates the PNDM phenotype [31] . However, mice completely lacking K ATP channels (by knocking out either the SUR1 or Kir6.2 subunit) do not completely reiterate the CHI phenotype. In K ATP channel KO mice, hypersecretion reportedly occurs immediately after birth, but rapidly progresses to a relative undersecretion [12] [13] [14] 17] . K ATP channels are distributed throughout the body and, conceivably, lack of K ATP in other tissues contributes to the hyperinsulinaemia and secondary progression in Kir6.2
or SUR1 −/− animals [32] [33] [34] [35] . Lack of K ATP in skeletal muscle causes enhanced basal and insulin-stimulated glucose uptake [32] . Activation of K ATP channels in the mediobasal hypothalamus can lower blood glucose through inhibition of hepatic gluconeogenesis and SUR1 −/− mice are resistant to this inhibitory action [35] . It is important to bear these complex positive and negative effects of K ATP KO on lowering of blood glucose in mind, but at this point it is unclear how they will play out in terms of the wholeanimal progression.
In terms of insulin secretory phenotype, recent papers on SUR1 KO mice have shown somewhat contradictory results, even demonstrating a basal insulin hypersecretion and maintained insulin secretion at high glucose concentrations [36, 37] . A full explanation for the complexity of the results is yet to be achieved, although there is clear evidence that glutamine and other amino acids can potently stimulate secretion in these SUR1 KO islets [37, 38] . These mice also exhibit near-normal insulin secretion in response to feeding, which could account for the euglycaemia [12] . Nevertheless, in terms of modelling CHI, it is clear that mice with a complete absence of beta cell K ATP channels are glucose-intolerant and neither persistently hyperinsulinaemic nor hypoglycaemic.
Conversely, mice expressing a dominant-negative Kir6.2[AAA] transgene in beta cells show an incomplete reduction of K ATP channel activity (∼70%) and demonstrate both an enhanced glucose stimulation of insulin secretion and hyperinsulinism that persists through adulthood [15] . As discussed below, we suggest that genetic suppression of K ATP activity leads to enhanced excitability and insulin secretion, but with potentially different long-term consequences depending on severity of the suppression: incomplete loss of K ATP (e.g. Kir6.2[AAA] mice) causes a maintained hyperinsulinism whereas complete loss may transiently cause hypersecretion, followed by a secretory deficit and reduced glucose tolerance. In the present study, heterozygous Kir6.2 +/− or SUR1 +/− mice are both shown to have a significant (∼60%) reduction of K ATP channel activity in islets, presumably distributed uniformly among all beta cells. Consistent with the proposed hypothesis, these mice demonstrate a similar hyperinsulinaemic phenotype to Kir6. (Figs. 3 and 6 ). In part these differences may be the result of strain differences: we did not perform the multiple backcrosses of the SUR1 −/− mice necessary to reach isogenicity. In addition, K ATP channels in skeletal muscle are formed from Kir6.2 plus SUR2A [32, 39] , which will mean that Kir6.2 KO mice (but not SUR1 KO mice) will have increased peripheral glucose sensitivity, which may contribute to maintenance of glucose tolerance.
Beta cell hyperexcitability and secretory phenotype: an 'inverse-U' model We have thus further proposed [18] , and the data here support, an inverse-U model [40] for the general beta cell response to hyperexcitability generated by alterations of K + (or other) conductances (Fig. 7) . The essence of the model is that as excitability increases, there is an expected hypersecretory response to glucose, but as excitability is increased above a threshold, either developmentally (e.g. in K ATP KO animals [12] [13] [14] ) or in response to altered stimulatory conditions (e.g. high-fat diet [18] ), a secondary loss of secretory capacity leads to relative hypoinsulinaemia and glucose intolerance. Graded degrees of hyperexcitability will lead to graded enhancements of insulin secretion until, above some threshold, beta cells are driven to insulin secretory failure. At this juncture, we can only speculate on the trigger behind the secondary secretory [15] , would thus be positioned on the 'ascending' limb of the inverse-U progression (Fig. 7) . Conversely, Kir6.2 −/− or SUR1 −/− mice, which have maximal hyperexcitability, and high [Ca 2+ ] i even at low glucose concentration [14, 42] , would be positioned on the 'descending' limb (Fig. 7) . It also predicted that an increase of K ATP density, or loss of sensitivity to inhibitory glucose, would lead to reduced islet excitability and secretory response. Transgenic mice expressing mutant beta cell K ATP channels (Kir6.2[ΔN30]) with reduced ATP sensitivity (and presumably reduced glucose sensitivity) do have a severely undersecreting phenotype [31] , and this appears to be the mechanism of PNDM in humans [22, 23, 43] . We can thus add an extension of the 'ascending' limb into the region of subnormal excitability (Fig. 7) . [5-7, 29, 30, 44] . While mice with reduced beta cell K ATP reiterate a hyperinsulinaemic phenotype (this study and [15] ), mice completely lacking beta cell K ATP activity unexpectedly show glucose intolerance and loss of GSIS as adults [12] [13] [14] . One implication of these findings is that persistent hyperinsulinism in humans might reflect incomplete loss of K ATP . The phenotype of many CHI mutations in recombinant expression [5, 30, 44] would actually suggest that a reduced, but not complete, absence of K ATP channels [45] is likely. Consistent with this idea, Henwood et al. [46] have recently demonstrated that some CHI patients with K ATP channel mutations must maintain some K ATP channel activity, since the patients were responsive to the K ATP channel drugs tolbutamide and diazoxide. Although carriers of loss-of-function (but not complete KO) SUR1 mutations have reportedly normal glucose tolerance and insulin secretion [47] , we may suggest that heterozygous carriers of complete KO mutations might have enhanced glucose tolerance and subclinical hyperinsulinism. Interestingly, one of the early studies of human CHI mutations reported a homozygous Kir6.2 truncation mutation in an affected patient [6] , but unfortunately, there were no clinical data on the heterozygous parents.
A second implication is that in humans with severe loss of K ATP , a progression from hyperinsulinaemia to glucose intolerance might be expected, as seen in K ATP KO mice [12] [13] [14] [15] . Although only limited data are available, there are reports that some CHI patients, even those non-surgically treated, can spontaneously progress to diabetes [7, 48, 49] . In addition, we have shown that normally hypersecreting Kir6.2[AAA] transgenic mice on a Kir6.2 +/− background (which, although untested, presumably have a greater reduction in K ATP channel activity than each genotype alone), but not Kir6.2 +/− mice, can progress from a hypersecreting phenotype to an undersecreting diabetic phenotype, when challenged by a highfat diet [18] . We may thus speculate that any mechanism causing hyperexcitability of islets, for example by decreasing K ATP channel density or activity, will cause an initially hypersecreting phenotype. However, further increase in excitability, above some threshold, can progress to an undersecretory diabetic phenotype. Such a progression has potential parallels to the typical progres- Fig. 7 'Inverse-U' model for the progressive response of the beta cell to increasing excitability. Kir6.2 +/+ islets represent the normal secretory responsiveness to glucose. Both Kir6.2[AAA] (∼60% decrease of K ATP [15] ) and Kir6.2 +/− islets (∼60% reduction in K ATP channel density, present work) show a similar hyperinsulinaemic phenotype, placing these two independent mouse models of decreased K ATP channel activity on the 'ascending' limb. Kir6.2 −/− islets with maximally enhanced excitability (100% decrease of K ATP ) show an undersecretory phenotype as adults [12] [13] [14] , placing them on the 'descending' limb sion of type 2 diabetes-from compensatory insulin hypersecretion to beta cell failure.
